The Battle of Giants exists to answer one important question: Is a company’s latest strategy the most effective way to grow? We research the core problem a strategy addresses, compare it to alternatives and evaluate execution risks. Sifting through data and lessons from history. We focus on mass market retail, big media, and transportation - industries undergoing major disruptions. Excerpts of our investigations are published here on SA; visit our website for full reports.
Founder & Editor of EPB Macro Research
EPB Macro Research: uses macroeconomic analysis to create an easily replicable portfolio of ETFs, specifically designed to limit drawdowns, reduce volatility and improve total return over a long-term time horizon.
Background: I earned my B.A in Economics from New York University. Upon graduation, I worked at Morgan Stanley in Wealth Management and after as an analyst at Panorama Partners, a quantitative hedge fund specializing in equity derivatives.
I married my diverse background in economic analysis from NYU with my computer programming and statistical knowledge, gained from the hedge fund, to create EPB Macro Research in the summer of 2017.
Disclaimer: EPB Macro Research is published as an information service. It includes opinions as to buying, selling and holding various stocks and other securities.
However, the publishers of EPB Macro Research are not brokers or acting as investment advisers and do not provide investment advice or recommendations directed to any particular subscriber or in view of the particular circumstances of any particular person.
All data is supplied by sources is believed to be reliable, and the calculations herein are made using such data, and that such calculations are not guaranteed by these sources, the information providers, or any other person or entity, and may not be complete.
EPB Macro Research does not guarantee that you will out-perform the stock market.
The information provided by EPB Macro Research is obtained from sources believed to be reliable but is not guaranteed as to accuracy or completeness.
At various times, the publishers and employees of EPB Macro Research may own, buy or sell the securities discussed for purposes of investment or trading. Eric Basmajian invests his own portfolio primarily in stocks recommended in the EPB Macro Research newsletter.
EPB Macro Research and its publishers, owners and agents, are not liable for any losses or damages, monetary or otherwise, that result from the content of EPB Macro Research.
Past results are not necessarily indicative of future performance.
I am a retired professor, a retired investment adviser, and currently a private investor and full-time tennis pro. I bought my first stock in a custodial account in 1958. I am a student of history, particularly military and economic/market history. The intellectual passions of my retirement years have been markets, mathematics, and quantum theory. Recently I have found myself reading book after book on the thoughts and feelings of animals, and I believe they are subtly influencing some of my views. I have a cat I like a lot. I like to travel. I served in Vietnam.
As a professional in commercial real estate, my investment focus is on REITs. My goal is to provide detailed research on the properties being acquired and sold by REITs, as the quality and value of the real estate purchased by a REIT has an impact on the long term health of a REIT.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaboration with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI) marketplace research is delivering robust returns since inception. To name a couple winners, Nektar Therapeutics and Spectrum Pharmaceuticals delivered profits of 446% and 196% for our subscribers, respectively. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios. Of note, we’ll increase our price soon (SUBSCRIBE to IBI now to lock in the current price and save money). Click the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs. To read the FREE once-weekly articles covering promising small-cap bioscience firms, check out www.drtranbiosci.com (and make sure to register for our mailing list). You can read up on Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html "Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."
Philstockworld.com is the fastest growing stock and option newsletter on the Web. "High Finance for Real People - Fun and Profits" is our motto and our Basic and Premium Chat Sessions offer readers a chance to speak to Phil live during the trading day as well as authors like Optrader, Sabrient, Income Trader and Trend Trader - who send out Alerts during the market sessions and discuss trade ideas live with Members. We even have a new low-cost "Trend Watcher" Membership that lets readers view our chat sessions without directly participating a great solution for people who want to test-drive the site and profit from our experience! Trend Watchers get to view all of our Chat Archives, weekly Webinars - as well as the amazing PSW Wiki, which gives you Phil's recent opinions and trade ideas as well as technical and fundamental analysis of hundreds of stocks that we follow. Philip R. Davis is a founder of Phil's Stock World (www.philstockworld.com), a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders. Mr. Davis is a serial entrepreneur, having founded software company Accu-Title, a real estate title insurance software solution, and is also the President of the Delphi Consulting Corp., an M&A consulting firm that helps large and small companies obtain funding and close deals. He was also the founder of Accu-Search, a property data corporation that was sold to DataTrace in 2004 and Personality Plus, a precursor to eHarmony.com. Phil was a former editor of a UMass/Amherst humor magazine and it shows in his writing -- which is filled with colorful commentary along with very specific ideas on stock option purchases (Phil rarely holds actual stocks). Visit: Phil's Stock World (www.philstockworld.com)
2016 returns: 22.40%
2017 returns: 22.05%
The REIT Forum is in the top 1% on TipRanks: http://bit.ly/cwmftip
The REIT Forum focuses on risk-adjusted returns with a defensive strategy. With a strong background in accounting and finance, fundamentals are a top priority. Buying a strong company with great fundamentals at an attractive price is a good long-term strategy. The subscription platform allows me to do a few things very well. It allows me to share the research I’m doing for my own investment decision making. It allows me to communicate rapidly with investors that are willing to pay for my best work.
The REIT Forum includes:
Subscriber only – Extensive research (thousands of articles) on 50+ companies, buy targets, and forward looking analysis.
Subscriber only - Weekly articles comparing 50+ preferred shares and finding the best opportunities. Preferred shares offer investors high yields with relatively lower risk.
Subscriber only - Analysis and updates on the REIT sectors. This includes finding the best investments within a subsector.
Subscriber only – Risk ratings and dividend sustainability research.
What is my view on risk?
The traditional view is to see earning excess returns as compensation for taking on high levels of risk. I believe it is far better to focus on earning returns from catching market failures. These failures happen due to poor liquidity and investors (including analysts) working with incomplete information. I believe that by knowing the individual companies well, the investor can step in when the “risk” is heavily skewed in favor of “returns”.
I do not try to generate higher returns, I try to generate more consistent returns by reducing the downwards risk. Occasionally that results in exceptionally high returns when something corrects, but it also means I am willing to pass on several decent opportunities because I want the risk/return profile skewed heavily in my favor.
John S. Rhodes is the founder of the Digital Coin Collective. The DCC is a premium research service that focuses on money-getting Bitcoin, Ethereum and blockchain investments. Special attention is given to "off the radar" lucrative cryptocurrency investing situations such as initial coin offerings (ICO's), government deep think, BigCo blue chip, fintech software and services. Exclusive digital money investment ideas, alt-coin insights, and unique resources are also available for members only.
MBBS, MD, MBA (NYU-Stern, Finance): worked/did research at Cornell and Harvard Affiliated Hospitals
Portfolio Manager/founder for own US biotech/pharma-focused asset management firm, Vasuda Capital Management (vasudacapitalmanagement.com).
Founder/Editor: Vasuda Healthcare Analytics: SA Marketplace premium biotech/pharma research service
Founder and Sponsor: Vasuda Global Orphan/Rare Diseases Index, first global equity index representing the orphan/rare disease sector (vasudaindices.com), index calculator=Solactive A.G. https://www.vasudaindices.com
Investor/Trader in biotech and tech sectors for 10 years. Founder & Editor of ROTY (Runners of the Year), a strategy and now Marketplace Service focused on discovering opportunities to achieve high % gains within a year´s time frame.
Importantly, I often highlight risk management and entry/exit strategies, as I believe they represent areas that are often neglected but materially important for readers to understand and apply if they want to be profitable long term.
Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.
Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.
If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research
Disclaimer - we are not investment advisors.
Founder and Director of Gerring Capital Partners.
Publisher of Retirement Sentinel marketplace service on Seeking Alpha.
Visiting Lecturer at Ursinus College in the Department of Business and Economics.
Faculty Advisor to the Ursinus College Finance Scholars.
To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 6 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
"The person that turns over the most rocks wins the game" - Peter Lynch
I like to turn over a lot of rocks with my research to find the truly exceptional companies.
My Marketplace Service, Harry's High-Quality Club, is where I highlight my best findings in detail.
I'm also currently a CFA candidate. I passed the level 1 exam in June 2015.
I have been an investor since 1982 , following my Dad and Grandfather.. My main interest is contrarian indicators, and long term proven dividend growth stocks in mundane industries. My watch list gets its start with the fine analysis of the various authors here at SA, then I screen it down to a list of approx. 45 companies using my own due diligence.
please see my blog posts here providing more detail on the free & public indicators I mention in some comments I post here at SA. It is intended to help anyone interested to dig into this and verify it for themselves. These indicators are a big help in providing a disciplined approach as to "when" to buy.
Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace Offerings:
The Insiders Forum | The Biotech Forum | Busted IPO Forum
Retired electrical engineer. Now a writer, investor, and consultant. I have written financial articles for SA, Motley Fool, Benzinga, Investor Place. Now I write for fun on my personal blog "The Mathematical Investor": https://mathman6577.wordpress.com. You can follow me on Twitter at @mathman6577. If you're an "early retiree" like me check out the Facebook page https://www.facebook.com/earlyretirees/.
My portfolio consists of the following:
(A) 401k: Large and mid/small cap index funds (US and International), UTX, stable value (fixed income) fund
(B) Taxable brokerage account: KO , AAPL, PG, JNJ, T, CVX, MMP, AFL, CVS, NWE, WMT, FTBFX, TROW , EMR, PINCX, RTN, WEC
(C) IRA: NHI, ES, MCD, CB
I use the "Bucket Approach" for asset allocation:
Bucket A: Emergency fund + planned expenses within the next 2 years = cash account
Bucket B: Next eight years of expenses = fixed income accounts (used to replenish Bucket A when empty)
Bucket C: Expenses ten to thirty years down the road = dividend stocks + index funds (used to replenish Bucket B when empty.
Avi Gilburt is founder of ElliottWaveTrader.net, a live trading room and member forum focusing on Elliott Wave market analysis with over 3000 members and over 450 money manager clients. Avi emphasizes a comprehensive reading of charts and wave counts that is free of personal bias or predisposition.
Avi is an accountant and a lawyer by training. His education background includes his graduating college with dual accounting and economics majors, and he then passed all four parts of the CPA exam at once right after he graduated college. He then earned his Juris Doctorate in an advanced two and a half year program at the St. John’s School of Law in New York, where he graduated cum laude, and in the top 5% of his class. He then went onto the NYU School of Law for his masters of law in taxation (LL.M.).
Before retiring from his legal career, Avi was a partner and National Director at a major national firm. During his legal career, he spearheaded a number of acquisition transactions worth hundreds of millions to billions of dollars in value. So, clearly, Mr. Gilburt has a detailed understanding how businesses work and are valued.
Yet, when it came to learning how to accurately analyze the financial markets, Avi had to unlearn everything he learned in economics in order to maintain on the correct side of the market the great majority of the time. In fact, once he came to the realization that economics and geopolitics fail to assist in understanding how the market works, it allowed him to view financial markets from a more accurate perspective.
For those interested in how Avi went from a successful lawyer and accountant to become the founder of Elliottwavetrader.net, his detailed story is linked here.
Since Avi began providing his analysis to the public, he has made some spectacular market calls which has earned him the reputation of being one of the best technical analysts in the world.
As an example of some of his most notable astounding market calls, in July of 2011, he called for the USD to begin a multi-year rally from the 74 region to an ideal target of 103.53. In January of 2017, the DXY struck 103.82 and began a pullback expected by Avi.
As another example of one of his astounding calls, Avi called the top in the gold market during its parabolic phase in 2011, with an ideal target of $1,915. As we all know, gold hit a high of $1,921, and pulled back for over 4 years since that time. The night that gold hit its lows in December of 2015, Avi was telling his subscribers that he was on the phone with his broker buying a large order of physical gold, while he had been accumulating individual miner stocks that month, and had just opened the EWT Miners Portfolio to begin buying individual miners stocks due to his expectation of an impending low in the complex.
One of his most shocking calls in the stock market was his call in 2015 for the S&P500 to rally from the 1800SPX region to the 2600SPX region, whereas it would coincide with a “global melt-up” in many other assets. Moreover, he was banging on the table in November of 2016 that we were about to enter the most powerful phase of the rally to 2600SPX, and he strongly noted that it did not matter who won the 2016 election in the US, despite many believing that the market would “crash” if Trump would win the election. This was indeed a testament to the accuracy of the Fibonacci Pinball method that Avi developed.
I am a biotech investor with a PhD in Biochemistry and Molecular Biology. I hope to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!
Over 35 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action; and biotech. Background as a physician and pharmaceutical inventor and entrepreneur.
My job has nothing to do with the financial world, on the contrary - I have a college education and a Ph.D. in science and I work for a large cooperation in the German industry. I bought my first stocks almost 20 years ago, starting with investments in DAX companies (the German large cap index) and have continuously broadened my horizon geographically and to other equity classes since then. My main ambition is to obtain financial independence and the admittedly challenging ultimate goal is to retire at the age of 50 (or at least in the mid-fifties). Let’s see how this turns out…
I am a former investment advisor and owner of several businesses, and consequently everything related to business - including investing, macro-economics, and emerging products and services come under my research and interests radar.
The most interesting and important to me are the entertainment industry, commodities, BRICs, and the impact of loose money policies on businesses and investors.
These days I invest only for myself, while continuing to write on a variety of financial and economic topics.
Strong Bio is a growth-focused analyst seeking identification of unique investment opportunities in biotechnology that arise as high probability market niche innovation or expansion based on scientific peer-reviewed evidence supportive of novel mechanism(s) of action. By diligently screening investment candidates in multiple biotechnology sectors, initial position recommendations and reinforcing position pricing profiles can be systematically evaluated citing fundamental trends for investors to exploit. If you would like to request that Strong Bio publish an article on a company of interest, please request by private message. Strong Bio reminds the reader that investment in biotechnology can be considered high risk, and diversification of assets is a necessity. Strong Bio is a personal branding of F. Thomas Crump, Ph.D., in an attempt to communicate with a biotechnology stock club that got too large to communicate with by text. Strong Bio mobile app under construction.